Patient and Physician Knowledge of Key Safety Messages
Completed
- Conditions
- Anticoagulation
- Registration Number
- NCT01907048
- Lead Sponsor
- Bayer
- Brief Summary
This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2227
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Knowledge and understanding among physicians regarding key safety information contained in the prescriber guide assessed by web-based questionnaire Up to 18 months Knowledge and understanding of patients regarding the key safety information contained in the patient alert card assessed by paper-based questionnaire Up to 18 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of Rivaroxaban (Xarelto) influence anticoagulation efficacy and safety in patients?
How does Rivaroxaban (Xarelto) compare to warfarin and other NOACs in managing anticoagulation therapy safety profiles?
Are there specific biomarkers that correlate with Rivaroxaban (Xarelto) adherence and understanding of safety messages in anticoagulated patients?
What adverse events are most commonly associated with Rivaroxaban (Xarelto) use in anticoagulation therapy and how are they managed?
How do alternative anticoagulants like Apixaban or Dabigatran address similar safety concerns as the Xarelto Risk Minimisation Plan?